Select a medication above to begin.
Tirabrutinib
tirabrutinib
Adult Dosing .
Dosage forms: TAB: 480 mg
Investigational New Drug (IND)
- [pending FDA approval]
primary central nervous system lymphoma, relapsed or refractory
- [indication/patient population pending FDA approval]
- Info: inhibits BTK activity, including B-cell antigen receptor and cytokine receptor pathways, leading to inhibition of malignant B-cell proliferation and tumor growth
Peds Dosing .
- Dosage forms: --
Investigational New Drug (IND)
- [pending FDA approval]
- Info: not anticipated to be applicable to Peds population
Contraindications / Cautions .
- pending FDA approval
Drug Interactions .
Overview
tirabrutinib
- pending FDA approval
- pending FDA approval
Safety/Monitoring .
pending FDA approval
Pharmacology .
Metabolism: pending FDA approval
Excretion: pending FDA approval
Subclass: Kinase Inhibitors, BTK Inhibitors
Mechanism of Action
pending FDA approval
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.